{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T23:44:38Z","timestamp":1771371878357,"version":"3.50.1"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T00:00:00Z","timestamp":1640217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Transcatheter aortic valve replacement (TAVR) has developed to the therapy of choice for patients with symptomatic severe aortic stenosis who are unsuitable for surgical aortic valve replacement and elderly patients with intermediate or high operative risk. However, the optimal anticoagulant therapy post-TAVR still remains a matter of debate.<\/jats:p><jats:p><jats:bold>Aims:<\/jats:bold> This study sought to investigate current anticoagulant treatment patterns and clinical outcome in patients undergoing TAVR.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> In a retrospective study based on anonymized health claims data of approximately seven million Germans with statutory health insurance (InGef database), anticoagulant treatment regimens were assessed using any drug prescription post discharge within the first 90 days after TAVR procedure. Clinical events between 30 days and 6 months were examined by treatment regime.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> The study population comprised 4,812 patients with TAVR between 2014 and 2018: 29.4% received antiplatelet monotherapy, 17.8% dual antiplatelet therapy, 17.4% oral anticoagulation (OAC) plus antiplatelet therapy, 12.9% OAC monotherapy, 2.2% triple therapy and 19.2% did not receive any anticoagulatory drugs. Sixty-four percentage of patients with OAC received direct oral anticoagulants (DOAC). Hence, 68% of all patients were treated non-adherent to current guidelines. Forty percentage of patients with OAC prior to TAVR did not have any OAC after TAVR. The adjusted risk of all-cause mortality was significantly increased in patients with OAC (HR 1.40, 95% CI 1.03\u20131.90, <jats:italic>p<\/jats:italic> = 0.03) and no anticoagulatory treatment (HR 3.95, 95% CI 2.95\u20135.27, <jats:italic>p<\/jats:italic> &amp;lt; 0.0001) when compared to antiplatelet monotherapy.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> This large real-world data analysis demonstrates substantial deviations from guideline recommendations and treatment after TAVR. Considering relevant differences in clinical outcome across treatment groups, major effort is warranted to examine underlying causes and improve guideline adherence.<\/jats:p>","DOI":"10.3389\/fcvm.2021.780762","type":"journal-article","created":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T10:22:26Z","timestamp":1640254946000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Real-World Anticoagulatory Treatment After Transcatheter Aortic Valve Replacement: A Retrospective, Observational Study on 4,800 Patients"],"prefix":"10.3389","volume":"8","author":[{"given":"Christopher","family":"Hohmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jochen","family":"Walker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hendrik","family":"Wienemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Baldus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roman","family":"Pfister","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1093\/eurheartj\/ehx391","article-title":"2017 ESC\/EACTS guidelines for the management of valvular heart disease","volume":"38","author":"Baumgartner","year":"2017","journal-title":"Eur Heart J."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1016\/S0140-6736(16)30073-3","article-title":"Transcatheter aortic valve replacement versus surgical valve replacement in intermediate risk-patients: a propensity score analysis","volume":"387","author":"Thourani","year":"2016","journal-title":"Lancet."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1514616","article-title":"Transcatheter or surgical aortic-valve replacement in intermediate-risk patients","volume":"374","author":"Leon","year":"2016","journal-title":"N Engl J Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"129","DOI":"10.4244\/EIJV8I1A20","article-title":"Risk of stroke after transcatheter aortic valve implantation (TAVI): a meta-analysis of 10,037 published patients","volume":"8","author":"Eggebrecht","year":"2012","journal-title":"EuroIntervention."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1056\/NEJMoa1202277","article-title":"Transcatheter aortic valve replacement for inoperable severe aortic stenosis","volume":"366","author":"Makkar","year":"2012","journal-title":"N Engl J Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1016\/S0140-6736(17)30757-2","article-title":"Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study","volume":"389","author":"Chakravarty","year":"2017","journal-title":"Lancet."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1093\/eurheartj\/ehx294","article-title":"SOURCE 3: 1-year outcomes post-transcatheter aortic valve implantation using the latest generation of the balloon expandable transcatheter heart valve","volume":"38","author":"Wendler","year":"2017","journal-title":"Eur Heart J"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jcin.2017.09.034","article-title":"1-Year clinical outcomes in women after transcatheter aortic valve replacement: results from the first WIN-TAVI Registry","volume":"11","author":"Chieffo","year":"2018","journal-title":"JACC Cardiovasc Interv."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1016\/j.jtcvs.2012.03.001","article-title":"2012 ACCF\/AATS\/SCAI\/STS expert consensus document on transcatheter aortic valve replacement: developed in collaboration with the American heart association, American society of echocardiography, European association for cardio-thoracic surgery, heart failure society of America, mended hearts, society of cardiovascular anesthesiologists, society of cardiovascular computed tomography, and society for cardiovascular magnetic resonance","volume":"144","author":"Holmes DR","year":"2012","journal-title":"J Thorac Cardiovasc Surg"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/eurheartj\/ehab626","article-title":"2021 ESC\/EACTS guidelines for the management of valvular heart disease","author":"Vahanian","year":"2021","journal-title":"Eur Heart J."},{"key":"B11","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1161\/CIRCULATIONAHA.110.946533","article-title":"Incidence and predictors of early and late mortality after transcatheter aortic valve implantation in 663 patients with severe aortic stenosis","volume":"123","author":"Tamburino","year":"2011","journal-title":"Circulation."},{"key":"B12","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1093\/eurheartj\/ehw658","article-title":"Increased use of oral anticoagulants in patients with atrial fibrillation: temporal trends from 2005 to 2015 in Denmark","volume":"38","author":"Gadsboll","year":"2017","journal-title":"Eur Heart J."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1016\/j.jacc.2017.03.540","article-title":"Influence of direct oral anticoagulants on rates of oral anticoagulation for atrial fibrillation","volume":"69","author":"Marzec","year":"2017","journal-title":"J Am Coll Cardiol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"Eikelboom","year":"2013","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1055\/s-0039-1683422","article-title":"Non-vitamin K oral anticoagulants in comparison to phenprocoumon in geriatric and non-geriatric patients with non-valvular atrial fibrillation","volume":"119","author":"Hohmann","year":"2019","journal-title":"Thromb Haemost."},{"key":"B16","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/pds.3895","article-title":"Characteristics and external validity of the German Health Risk Institute (HRI) Database","volume":"25","author":"Andersohn","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1016\/j.jcin.2020.09.013","article-title":"Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation after TAVR","volume":"13","author":"Kawashima","year":"2020","journal-title":"JACC Cardiovasc Interv."},{"key":"B18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ahj.2018.06.006","article-title":"Variation in post-TAVR antiplatelet therapy utilization and associated outcomes: insights from the STS\/ACC TVT registry","volume":"204","author":"Sherwood","year":"2018","journal-title":"Am Heart J."},{"key":"B19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jacc.2018.08.1045","article-title":"Long-term mortality and early valve dysfunction according to anticoagulation use: the FRANCE TAVI registry","volume":"73","author":"Overtchouk","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3390\/geriatrics5030044","article-title":"Changes in treatment of very elderly patients six weeks after discharge from geriatrics department","volume":"5","author":"Dipanda","year":"2019","journal-title":"Geriatrics (Basel)."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1016\/j.amjcard.2011.07.049","article-title":"Dual antiplatelet therapy versus aspirin alone in patients undergoing transcatheter aortic valve implantation","volume":"108","author":"Ussia","year":"2011","journal-title":"Am J Cardiol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.ijcard.2014.04.170","article-title":"SAT-TAVI (single antiplatelet therapy for TAVI) study: a pilot randomized study comparing double to single antiplatelet therapy for transcatheter aortic valve implantation","volume":"174","author":"Stabile","year":"2014","journal-title":"Int J Cardiol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/j.jcin.2017.04.014","article-title":"Aspirin versus aspirin plus clopidogrel as antithrombotic treatment following transcatheter aortic valve replacement with a balloon-expandable valve","volume":"10","author":"Rodes-Cabau","year":"2017","journal-title":"JACC Cardiovasc Interv."},{"key":"B24","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1056\/NEJMoa2017815","article-title":"Aspirin with or without clopidogrel after transcatheter aortic-valve implantation","volume":"383","author":"Brouwer","year":"2020","journal-title":"N Engl J Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s00059-017-4643-5","article-title":"Management of valvular heart disease: ESC\/EACTS guidelines 2017","volume":"42","author":"Haude","year":"2017","journal-title":"Herz."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e576S","DOI":"10.1378\/chest.11-2305","article-title":"Antithrombotic and thrombolytic therapy for valvular disease: antithrombotic therapy and prevention of thrombosis: American college of chest physicians evidence-based clinical practice guidelines","volume":"141","author":"Whitlock","year":"2012","journal-title":"Chest J"},{"key":"B27","doi-asserted-by":"publisher","first-page":"3155","DOI":"10.1093\/eurheartj\/ehu298","article-title":"Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrom and\/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European society of cardiology working group on thrombosis, European heart rhythm association (EHRA), European association of percutaneous cardiovascular interventions (EAPCI) and European association of acute cardiac care (ACCA) endorsed by the heart rhythm society (HRS) and Asia-pacific heart rhythm society (APHRS)","volume":"35","author":"Lip","year":"2014","journal-title":"Eur Heart J."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding events in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N Engl J Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N Engl J Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1080\/14779072.2020.1755260","article-title":"Extended oral anticoagulation after incident venous thromboembolism \u2013 a paradigm shift?","volume":"18","author":"Albertsen","year":"2020","journal-title":"Expert Rev Cardiovasc Ther."},{"key":"B31","doi-asserted-by":"publisher","first-page":"303","DOI":"10.5114\/aic.2016.63629","article-title":"Triple anticoagulation therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention \u2013 real life assessment","volume":"4","author":"Bogacki","year":"2016","journal-title":"Adv Interv Cardiol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1186\/s12872-020-01582-2","article-title":"Efficacy and safety outcomes in novel oral anticoagulants versus vitamin-K antagonists on post-TAVI patients: a meta-analysis","volume":"20","author":"Liang","year":"2020","journal-title":"BMC Cardiovasc Disord."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1016\/j.jcin.2019.03.003","article-title":"Oral anticoagulant type and outcomes after transcatheter aortic valve replacement","volume":"12","author":"Jochheim","year":"2019","journal-title":"JACC Cardiovasc Interv."},{"key":"B34","first-page":"15","article-title":"Oral anti-xa anticoagulation after trans-aortic valve implantation for aortic stenosis: the randomized Atlantis trial","author":"Collet","year":"2021","journal-title":"In Presented at: ACC21, May"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2111016","article-title":"Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR","author":"Van Mieghem","year":"2021","journal-title":"N Engl J Med"},{"key":"B36","first-page":"561","article-title":"Predictors of mortality in patients undergoing percutaneous aortic valve implantation","volume":"60","author":"Panico","year":"2012","journal-title":"Minerva Cardioangiol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1080\/14779072.2021.1924678","article-title":"Trends, predictors, and outcomes of major bleeding after transcatheter aortic valve implantation, from national inpatient sample (2011-2018)","volume":"19","author":"Zahid","year":"2021","journal-title":"Expert Rev Cardiovasc Ther."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1016\/j.jacc.2014.08.052","article-title":"Incidence, predictors, and prognostic impact of late bleeding complications after transcatheter aortic valve replacement","volume":"64","author":"Genereux","year":"2014","journal-title":"J Am Coll Cardiol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/j.jcin.2017.04.034","article-title":"Frequency, timing, and impact of access-site and non-access-site bleeding on mortality among patients undergoing transcatheter aortic valve replacement","volume":"10","author":"Piccolo","year":"2017","journal-title":"JACC Cardiovasc Interv."},{"key":"B40","first-page":"351","article-title":"Antithrombotika und Antih\u00e4morrhagika","volume-title":"Arzneiverordnungs-Report.","author":"Hein","year":"2016"},{"key":"B41","first-page":"531","article-title":"Antithrombotika und Antih\u00e4morrhagika","volume-title":"Arzneiverordnungs-Report","author":"Hein","year":"2019"},{"key":"B42","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/pds.3926","article-title":"Validation of low-dose aspirin prescription data in The Health Improvement Network: how much misclassification due to over-the-counter use?","volume":"25","author":"Soriano","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.780762\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T10:22:39Z","timestamp":1640254959000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.780762\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,23]]},"references-count":42,"alternative-id":["10.3389\/fcvm.2021.780762"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2021.780762","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,23]]},"article-number":"780762"}}